Thus, enhancing the PS with a delivery system containing a targeting component, in our case, the NGR peptide specific for aminopeptidase N (APN; CD13) and also cell-penetrating (R7), contributed to an increase in the Ce6 selectivity to tumor cells, which is undoubtedly a key element in the treatment of cancer. The gene discussed is RTN4R; the disease is cancer.